AGRX — Agile Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $9.80m
- $7.19m
- $19.59m
- 40
- 46
- 34
- 35
Annual cashflow statement for Agile Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -18.6 | -51.9 | -74.9 | -25.4 | -14.5 |
| Depreciation | |||||
| Non-Cash Items | 1.76 | 4.16 | 10.3 | -9.94 | -2.92 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.992 | 0.107 | -2.85 | -2.13 | 7.42 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -15.7 | -47.3 | -65.2 | -35.9 | -9.58 |
| Capital Expenditures | -0.098 | -0.353 | -0.269 | -0.133 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -40.3 | 39.7 | 0 | 0 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.098 | -40.7 | 39.5 | -0.133 | 0 |
| Financing Cash Flow Items | — | -1.06 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 42.4 | 68 | 30.4 | 22.2 | 6.89 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 26.6 | -20 | 4.68 | -13.9 | -2.69 |